Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3777-3780

  Matsumoto, Yoshiyuki ^a   Oka, Mikio ^a   Sakamoto, Akira ^a   Narasaki, Fumihiko ^a   Fukuda, Minoru ^a   Takatani, Hiroshi ^a   Terashi, Kenji ^a   Ikeda, Koki ^a   Tsurutani, Junji ^a   Nagashima, Seiji ^a   Soda, Hiroshi ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatin; Drug resistance; Immunohistochemistry; Lung cancer; Metallothionein

Indexed keywords

CISPLATIN; ETOPOSIDE; METALLOTHIONEIN; MITOMYCIN C; VINDESINE;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; METALLOTHIONEIN; MITOMYCIN; NEOPLASM PROTEINS; VINDESINE;

EID: 0031468380     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hamer DH: Metallothionein. Ann Rev Biochem 55: 913-951, 1986.
2. Kägi JHR and Schäffer A: Biochemistry of metallothionein. Biochemistry 27: 8509-8515, 1988.
3. Lazo JS and Basu A: Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Cancer Biol 2: 267-271, 1991.
4. Andrews PA: Mechanisms of acquired resistance to cisplatin. In: Anticancer drug resistance: advances in molecular and clinical research. (Goldstein LJ and Ozols RF, eds). Boston, Kluwer Academic Publisher, 1994, pp 217-248.
5. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
6. Scanlon KJ, Kashani-Sabet M, Tone T and Funato T: Cisplatin resistance in human cancers. Pharmac Ther 52: 385-406, 1991.
7. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
8. Murphy BJ, Laderoute KR, Chin RJ and Sutherland RM: Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. Cancer Res 54: 5808-5810, 1994.
9. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441, 1992.
10. Doyle AL: Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20: 326-337, 1993.
11. Webber MM, Rehman M and James GT: Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. Cancer Res 48: 4503-4508, 1988.
12. Murphy D, McGown AT, Crowther D, Mander A and Fox BW: Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63: 711-714, 1991.
13. Volm M and Mattern J: Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis 13: 1947-1950, 1992.
14. Kotoh S, Naito S, Sakamoto N, Goto K and Kumazawa J: Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 152: 1267-1270, 1994.
15. Mattern J and Volm M: Increased resistance to doxorubicin in human non-small cell lung carcinomas with metallothionein expression. Int J Oncol 1: 687-689, 1992.
16. Fujino S, Oka M, Sakamoto A, Fukuda M, Takatani H, Terashi K, Narasaki F, Ikeda K, Inoue Y, Kinoshita A, Soda H, Kanda T and Kohno S: The clinical implications of glutathione S-transferase-I expression in lung cancer: an immunohistochemical study. Oncology Rep 4: 311-313, 1997.
17. Kondo Y, Kuo S-M, Watkins SC and Lazo JS: Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55: 474-477, 1995.